Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways

BACKGROUND: Standard chemotherapy protocols in NSCLC are of limited clinical benefit. Histone deacetylase (HDAC) inhibitors represent a new strategy in human cancer therapy. In this study the combination of the HDAC inhibitor phenylbutyrate (PB) and the nucleoside analogue gemcitabine (GEM) was eval...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Schniewind, Bodo, Heintz, Kirsten, Kurdow, Roland, Ammerpohl, Ole, Trauzold, Anna, Emme, Doris, Dohrmann, Peter, Kalthoff, Holger
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2006
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1665446/
https://ncbi.nlm.nih.gov/pubmed/17123441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-3163-5-25
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares